Eradication of Helicobacter pylori: triple treatment scheme plus Lactobacillus vs. triple treatment alone

José Ernesto Sahagún-Flores; Luis Salvador López-Peña; Juan de la Cruz-Ramírez Jaimes; Mónica Susana García-Bravo; Rosalba Peregrina-Gómez; Javier Eduardo García de Alba-García

2007, Number 5

<< Back Next >>

Cir Cir 2007; 75 (5)

**Eradication of Helicobacter pylori: triple treatment scheme plus Lactobacillus vs. triple treatment alone**

Sahagún-Flores JE, López-Peña LS, Cruz-Ramírez JJ, García-Bravo MS, Peregrina-Gómez R, García de Alba-García JE

Full text

How to cite this article

Language: Spanish
References: 40
Page: 333-336
PDF size: 63.71 Kb.

ABSTRACT

Background: We undertook this study to determine the effectiveness of triple treatment associated with lactobacillus Casei strain Shirota against Helicobacter pylori, in comparison with triple conventional treatment without lactobacillus.
Methods: We designed a clinical comparative randomized study that included patients of both sexes infected by Helicobacter pylori. Patients were studied with endoscopy, biopsy and serology. Control group received traditional triple treatment with claritromicyn, amoxicilin and omeprazole, and the active group received the same treatment plus lactobacillus Casei strain Shirota. With the breath test at 8 weeks we determined the eradication of Helicobacter pylori.
Results: In the active group we included 31 patients. After treatment, in 29 persons (94 %) it was possible to eradicate the Helicobacter pylori. On the other hand, the control group was comprised of 33 patients who received only the traditional triple treatment; eradication was achieved in 25 patients (76 %). Significant differences (p ‹0.05) were observed in favor of active group treatment.
Conclusions: Traditional triple treatment plus lactobacillus Casei strain Shirota is associated with a higher frequency of eradication of Helicobacter pylori than triple treatment alone.

REFERENCES

1. Del Valle J. Úlcera péptica y trastornos relacionados. En: Jamson JL, editor. Principios de medicina interna. México: McGraw-Hill;2006. pp. 1924-1942.
2. Herrera MA. Gastritis. En: Halabe J, Lifshitz A, López J. Ramiro M, editores. México: McGraw-Hill Interamericana;1997. pp. 483-490.
3. Siavoshi F, Malekzadeh R, Daneshmand M, Ashktorab H. Helicobacter pylori: endemic and gastric disease. Dig Dis Sci 2005;50:2075-2080.
4. Lehours P, Megraud F. Helicobacter pylori infection and gastric MALT lymphoma. Rocz Akad Bialymst 2005;50:54-61.
5. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-1315.
6. Anon. NIH Consensus Conference Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-69.
7. Anon. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997;41:8-13.
8. Kang MS, Park DI, Yun JW, Oh SY, Yoo TW, Park JH, et al. Levofloxacin–azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;47:30-36.
9. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, et al. A prospective randomized trial of esomeprazole versus pantoprazol based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2393-2394.
10. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:79-83.
11. Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, et al. European Helicobacter pylori Study group. Aliment Pharmacol Ther 2002;16:167-180.
12. Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001;73(suppl):386S-392S.
13. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/ levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-1343.
14. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260-263.
15. Koebnick C, Wagner I, Ising K, Stern U. The effect of a probiotic beverage on gastrointestinal symptoms and general well-being in patients with chronic constipation. Emahrungs-Umschau 2001;48:392-396.
16. Drouin E. Helicobacter pylori: novel therapies. Can J Gastroenterol 1999;13:581-583.
17. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori, the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS. Immunol Med Microbiol 2002;32:105-110.
18. Armuzzi A, Creomoni F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-169.
19. Armazzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001;63:1-7.
20. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-1629.
21. Cremonini F, Canducci F, Di Caro S, et al. Helicobacter pylori treatment: a role for probiotics? Dig Dis 2001;19:144-147.
22. Vaira D, Holton J, Ricci C, et al. Review article: the transmission of Helicobacter pylori from stomach to stomach. Aliment Pharmacol Ther 2001;15(suppl 1):33-42.
23. Allaker RP, Young KA, Hardie JM, Domizio P, Meadows NJ. Prevalence of Helicobacter pylori at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. J Med Microbiol 2002;51:312-317.
24. Slick GD. Sexual transmission of Helicobacter pylori via oral-anal intercourse. Int J STD AIDS 2002;13:7-11.
25. Miyazaki M, Kato M, Takata T, Une H. Intrafamilial transmission of Helicobacter pylori: the association between a parent and an offspring with respect to the presence of anti-Cag antibody. J Infect Chemother 2002;8:70-75.
26. Dominici P, Bellentani S, Di Biasi AR, et al. Familial clustering of Helicobacter pylori infection: population based study. BMJ 1999;
319:537-541.
27. Ikue T, Yukiko T, Toshiaki S, et al. Helicobacter pylori intrafamilial infections: change in source of infection of a child from father to mother after eradication therapy. Clin Diagn Lab Immunol 2001;8:731-739.
28. De Schryver AA, Van Winckel MA. Helicobacter pylori infection: epidemiology and occupational risk for health care workers. Ann Acad Med Singapore 2001;30:457-463.
29. Kodaira MS, Escobar AM, Grisi S. Epidemiological aspects of Helicobacter pylori infection in childhood and adolescence. Rev Saude Publica 2002;36:356-369.
30. Feinstein AR. Clinical Biostatistics. St Louis: Mosby;1984.
31. Tokunaga K, Watanabe K, Tanaka A, Sugano H, Imase K, Ishida H, et al. Evaluation of 13C-urea breath test to confirm eradication of Helicobacter pylori. Nippon Shokakibyo Gakkai Zasshi 2005;102:176-182.
32. Sgouras D, Maragkoudakis P, Petraki K, Martínez-González B, Eriotou E, Michopoulus S, et al. In vitro and in vivo inhibition of Helicobacter pylori by lactobacillus Casei strain Shirota. Appl Environ Microbiol 2004;
70:518-516.
33. Cats A, Kuipers EJ, Bosschaert MAR, Pot RGJ, Vandenbroucke-Gauls CMJE, Kusters JG. Effect of frequent consumption of a lactobacillus Casei containing milk drink in Helicobacter pylori colonized subjects. Aliment Pharmacol Ther 2003;17:429-435.
34. Leandro-Liberato SV, Hernández-Galindo M, Torroba-Álvarez L, Sánchez-Miramón F, Leandro-Ciriza SE, Gómez-Abadia A, et al. Helicobacter pylori infection in the child population in Spain: prevalence, related factors and influence on growth. An Ped (Barc) 2005;63:489-494.
35. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;130:396S-402S.
36. Duggan C, Gannon J, Walker W. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 2002;75:789-808.
37. Watanabe T, Mike A. Properties and distribution of L. Casei. In Lactobacillus Casei Strain Shirota: Intestinal Flora and Human Health. Tokyo: Yakult Central Institute for Microbiological Research. Yakult Honsa Co. Ltd;1999. pp. 4-10.
38. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-de la Garza A, Dehesa M, González-Valencia G, Muñoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in México. J Clin Microbiol 2001;39:2677-2680.